NVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Given the recent negative sentiment from analysts, disappointing clinical trial results, ongoing investigation for securities fraud, and lack of strong technical or proprietary trading signals, Novo Nordisk does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The stock appears to be under significant pressure, and the investor's funds would be better allocated elsewhere until the company demonstrates a clearer path to recovery or positive catalysts emerge.
The stock is in a bearish trend with MACD negatively expanding, RSI indicating oversold conditions at 9.905, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support levels are at S1: 39.151 and S2: 36.14, with resistance levels at R1: 48.9 and R2: 51.911.
Hedge funds are increasing their positions, with buying activity up 112.57% over the last quarter. Additionally, the company reported modest YoY revenue and net income growth in Q4 2025.
The company is under investigation for potential securities fraud. Clinical trial results for CagriSema were disappointing, with Eli Lilly's competing drug showing superior efficacy. Analysts have significantly downgraded the stock, citing lack of near-term catalysts and reduced forecasts for key products. The gross margin also declined by 4.65% YoY.
In Q4 2025, revenue increased by 0.69% YoY, net income rose by 3.84% YoY, and EPS grew by 3.30% YoY. However, gross margin dropped by 4.65% YoY, indicating potential cost pressures or pricing challenges.
Analysts have downgraded the stock significantly, with multiple firms lowering price targets and ratings to Neutral or Hold. The consensus reflects concerns over disappointing clinical trial results and lack of near-term growth drivers.
